Professor Michael Hofman, a Nuclear Medicine Physician, leads the Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) at Melbourne's Peter MacCallum Cancer Centre. His groundbreaking research in PSMA PET and PSMA radioligand therapy has revolutionised prostate cancer imaging and treatment, resulting in FDA approval, Australian MBS funding, and a $2.1 billion investment by Novartis.

Hofman's passion for novel radiopharmaceuticals drives him to collaborate globally on Phase I, II, and III clinical trials, addressing unmet needs in oncology. As a key member of the Australasian Radiopharmaceutical Trials Network's scientific committee, he helped create a 10+ centre network across Australia, producing two landmark clinical trials published in The Lancet.

A highly sought-after speaker, Professor Hofman has given over 200 talks in 25+ countries at prominent conferences. His work has attracted more than $55 million in active grants, including a $15 million collaboration to develop next generation therapies for prostate cancer.

With 240+ peer-reviewed manuscripts and book chapters, Hofman has received numerous accolades, including the 2021 ACTA Clinical Trial of the Year Award and the 2018 SNMMI Image of the Year. Elected a fellow of the International Cancer Imaging Society in 2015, he has also expanded equitable access to PET funding in Australia.

As an educator, Professor Hofman co-authored the national Advanced Training Curriculum and supervises postgraduate researchers across various disciplines. He serves as an associate editor for prestigious journals including Journal of Nuclear Medicine and European Urology, leads Peter MacCallum's PET/CT program, and is a member of the Peter Mac Research Leadership Group.